Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3081398 | Neuromuscular Disorders | 2006 | 4 Pages |
Abstract
We report the use of continuous intravenous inotrope infusion as a palliative management strategy for the treatment of symptomatic, refractory, end stage cardiac dysfunction in patients with Duchenne muscular dystrophy. Milrinone and/or dobutamine administered by continuous intravenous infusion provided symptomatic and objective cardiovascular improvement up to 30 months in 3 individuals with Duchenne muscular dystrophy and severe dilated cardiomyopathy. Continuous inotrope infusion should be considered a practical treatment strategy for end stage cardiac dysfunction in Duchenne muscular dystrophy patients when cardiac transplantation is not a viable option.
Related Topics
Life Sciences
Neuroscience
Developmental Neuroscience
Authors
Linda H. Cripe, Brent J. Barber, Robert L. Spicer, Brenda L. Wong, Norbert Weidner, D. Woodrow Benson, Larry W. Markham,